Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical Officer
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Syncromune, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a groundbreaking platform technology that synchronizes in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the appointment of Jonathan Lewis, M.D., Ph.D., a leader and pioneer in immune therapies, to its executive management team as Chief Medical Officer.
“SYNC-T™ for solid tumor therapy has the potential to be a game changer, much like CAR T cells have been for leukemias and lymphomas,” said Dr. Lewis. “I am joining an exceptional convergence of clinical expertise, patient understanding and deep human caring, with a spectacular team of diversely talented people who are dedicated to revolutionizing cancer care. It is an honor, a privilege, and an exhilarating opportunity to be able to contribute to this remarkable technology and team. The initial clinical results in patients with solid cancers are truly amazing.”
Dr. Lewis brings extensive experience leading global translational and clinical research in the field of cancer and immunotherapies. Previously, he served as the Executive Chairman, CEO, and Chief Medical Officer of Ziopharm Oncology from 2004 to 2015, where he led the development of novel immunotherapies for metastatic cancers. Prior to Ziopharm, Dr. Lewis held the positions of Chairman and Chief Medical Officer of Antigenics, Inc, a company focused on personalized therapeutic vaccines for cancers, infectious diseases, and autoimmune disorders. His exceptional leadership skills have made him a sought-after board member, currently serving as Chairman of three boards and Director of two others.
At Memorial Sloan-Kettering Cancer Center in New York, Dr. Lewis made significant contributions as an attending surgeon in the Department of Surgery and as an attending physician in the Clinical Immunology Service, Division of Hematologic Oncology. He also held a professorship at Weill Medical College of Cornell University. Dr. Lewis holds an M.D. from Witwatersrand University in Johannesburg and a Ph.D. from Yale University. He has received extensive training at The Royal College of Surgeons in Edinburgh, Cambridge University, and Memorial Sloan-Kettering Cancer Center.
Dr. Lewis’ remarkable achievements also include raising over 1 billion US dollars in equity, nonprofit and government funding, as well as, leading companies to valuations in the multi billions. He is the recipient of numerous prestigious honors and awards in medicine and science, including the ASCO Young Investigator Award, the Kristen Carr Fellowship, the Yale University Ohse Fellowship, the Royal College of Surgeons Trubshaw Medal, the University of Cambridge Churchill Fellowship, the inaugural Kristen Ann Carr Fellowship, and the Sarcoma Foundation of America Hope and Vision Award.
Eamonn Hobbs, President and CEO of Syncromune expresses utmost confidence in Dr. Lewis’ appointment, stating, “We are delighted to welcome Dr. Lewis to our executive team. His unparalleled and extensive leadership experience at both publicly traded and private companies, unwavering dedication, and exceptional track record in advancing immunotherapies for cancer make him an invaluable addition to our organization. With Dr. Lewis’ leadership, we are poised to unlock new frontiers in solid tumor therapy and make a profound impact on patients’ lives.”
“Jon is an extremely accomplished physician and researcher and brings deep expertise in immuno-oncology drug development,” said Charles Link, M.D., Executive Chairman of Syncromune. “As we enter our next phase of growth, his leadership and expertise will be a critical component to driving our success as we move forward.”
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform drug technology optimized for solid tumor cancers that achieves the CAR T like efficacy demonstrated in liquid tumors. The company is currently developing SYNC-T™, a novel platform technology that uses a drug/device combination therapy. The platform is designed to achieve personalized T cell education, enabling the immune system to recognize and attack cancer throughout the body. The first 2 candidates, SV-101 and SV-102 are currently in Confirmatory Phase 1 trials. Syncromune is headquartered in Fort Lauderdale, FL, USA. For more information, please visit www.syncromune.com.
Syncromune® is developing SYNC-T™, a disruptive personalized in situ platform drug immunotherapy to educate T cells and stimulate the immune system to treat metastatic solid tumors where other therapies have failed. SYNC-T utilizes a combination approach of tumor activation and targeted delivery, aiming to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. To achieve tumor activation, a portion of a target tumor is lysed to generate immunogenic cell death and the release of Damage Associated Molecular Patterns (DAMPs) and tumor antigens, changing the tumor microenvironment by creating an in situ vaccine. The second component of the platform, targeted delivery, involves the intratumoral infusion of a proprietary fixed-dose combination drug with 4 active ingredients into the lysed portion of the tumor. This is designed to activate the immune system and combat immune suppression, resulting in patient-specific T cell education. The expansion of anti-cancer specific T cells can recognize and destroy cancer in the treated tumor as well as in metastases throughout the body.
This press release includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this press release or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as “plans,” “intends,” “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this press release or expressed orally in connection herewith are made only as of the date of this press release and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this press release; or (ii) the accuracy or completeness of any information contained in this press release, any other written information or oral information provided in connection herewith or any data that any of them generates. This press release was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune’s securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Some of the information contained in this press release may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.
EVP, Investor Relations & Corporate Communications
2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308